Posted by Michael Wonder on 18 Aug 2019
Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi
17 August 2019 - Roche has priced its personalised cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer and Eli Lilly that was approved last year.
Roche’s drug and Bayer/Lilly’s Vitrakvi target tumours with rare genetic anomalies called NTRK fusions, irrespective of where in the body the disease started.
Vitrakvi, co-developed by Bayer and Lilly’s Loxo Oncology, won approval in November, and is priced at $32,800 per month.
